Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2019 Financial Results on November 11, 2019
September 24 2019 - 7:30AM
Business Wire
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a
maker of medical devices and supplies and the developer of Helium
Plasma Technology, marketed and sold as Renuvion® in the cosmetic
surgery market and J-Plasma® in the hospital surgical market, today
announced that financial results for the third quarter of fiscal
year 2019 will be released after the market closes on Monday,
November 11.
Management will host a conference call at 4:30 p.m. Eastern Time
on November 11 to discuss the results of the quarter and to host a
question and answer session. To listen to the call by phone,
interested parties may dial 844-507-6493 (or 647-253-8641 for
international callers) and provide access code 8858026.
Participants should ask for the Apyx Medical Corporation Call. A
live webcast of the call will be accessible via the Investor
Relations section of the Company’s website and at:
https://event.on24.com/wcc/r/2078394/6C570DF79EE266DC31CAEA936370C638.
A telephonic replay will be available approximately two hours
after the end of the call through November 25, 2019. The replay can
be accessed by dialing 800-585-8367 for U.S. callers or
416-621-4642 for international callers and using the replay access
code: 8858026. The webcast will be archived on the Investor
Relations section of the Company’s website.
About Apyx Medical
Corporation:
Apyx Medical Corporation (formerly Bovie Medical Corporation) is
an advanced energy technology company with a passion for elevating
people’s lives through innovative products in the cosmetic and
surgical markets. Known for its innovative Helium Plasma
Technology, Apyx is solely focused on bringing transformative
solutions to the physicians and patients it serves. The company’s
Helium Plasma Technology is marketed and sold as Renuvion® in the
cosmetic surgery market and J-Plasma® in the hospital surgical
market. Renuvion® offers plastic surgeons, fascial plastic surgeons
and cosmetic physicians a unique ability to provide controlled heat
to the tissue to achieve their desired results. The J-Plasma®
system allows surgeons to operate with a high level of precision
and virtually eliminating unintended tissue trauma. The Company
also leverages its deep expertise and decades of experience in
unique waveforms through original equipment manufacturing (OEM)
agreements with other medical device manufacturers. For further
information about the Company and its products, please refer to the
Apyx Medical Corporation website at www.ApyxMedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190924005170/en/
Investor Relations Contact:
Westwicke Partners on behalf of Apyx Medical Corporation Mike
Piccinino, CFA investor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Apr 2023 to Apr 2024